Gene
ZBTB16
ZBTB16 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (7), Actionable biomarkers (1), Trial mentions (1), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ZBTB16. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
ZBTB16 has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 3 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 4 of 13,598 | 0.03% |
| 2021 | 0 of 8,692 | 0.00% | 4 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 3 of 14,459 | 0.02% |
| 2019 | 0 of 7,300 | 0.00% | 10 of 12,159 | 0.08% |
| 2018 | 0 of 6,927 | 0.00% | 10 of 11,854 | 0.08% |
| 2017 | 0 of 6,558 | 0.00% | 6 of 11,595 | 0.05% |
Showing 10 of 37 years.
Assay-provider ledger (7)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
| Arizona State University Biodesign Institute | Not a company | Clinical validation | 1 | September 01, 2015 |
| BECKMAN COULTER | Context dependent | Clinical validation | 1 | September 01, 2015 |
| Corning | Reagent supplier | Clinical validation | 1 | September 01, 2015 |
| DNASU (open reading frame repository) | Not a company | Clinical validation | 1 | September 01, 2015 |
Showing 5 of 7 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ZBTB16 undexpression | Lhrh Analogues Or Antagonists | responsive | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01226303 | Trial eligibility (AACT) |
Target-disease associations (997)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 15q11q13 microduplication syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 17q12 microduplication syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 3-M syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 3C syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 997 associations.
Vendor sourcing (5)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1303G>A (p.E435K) alteration is located in exon 3 (coding exon 2) of the ZBTB16 gene. This alteration results from a G to A substitution at nucleotide ... | View ClinVar record SCV003571581.2 |
| Associazione Italiana Ematologia Oncologia Pediatrica | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients with a clinical diagnosis of APL but subsequently found to have PLZF-RARα fusion or lacking PML-RARα, NPM-RARα or NuMA-RARα rearrangement shoul... | View trial NCT01226303 |
| Associazione Italiana Ematologia Oncologia Pediatrica | Trial sponsor | Mentioned in trial textTrial free-text mention | PLZF | View trial NCT01226303 |
| Hospital Israelita Albert Einstein | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | ACMG classification criteria: PM2, BP4 | View ClinVar record SCV002523681.1 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001033736.2 |
Trial-cited literature (67)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The effects of inhaled corticosteroids on healthy airways. | Allergy | 2024 | 12 |
| SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile. | Genome medicine | 2023 | 33 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations. | The Journal of hand surgery, European volume | 2023 | 8 |
| Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. | Nature medicine | 2022 | 112 |
Showing 5 of 67 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.R26T | 1 | 2019 | PMID 31554695 |
| p.W742C | 1 | 2015 | PMID 26000489 |
Literature-extracted relations (10)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Budesonide | Chemical | positive_correlate |
An inhaled dose of budesonide induces genes involved in transcription and signaling in the human airways: enhancement of anti- and proinflammatory effector genes. | 2016 |
| Tretinoin | Chemical | associate |
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. | 1998 |
| Polycystic Ovary Syndrome | Disease | associate |
Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. | 2018 |
| HIV Infections | Disease | associate |
Adaptive Reconfiguration of Natural Killer Cells in HIV-1 Infection. | 2018 |
| Inflammation | Disease | inhibit |
An inhaled dose of budesonide induces genes involved in transcription and signaling in the human airways: enhancement of anti- and proinflammatory effector genes. | 2016 |
Showing 5 of 10 relation assertions.
Organizations publishing (108)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 7 | 2013 to 2018 |
| University of Oxford | Academic | 6 | 2014 to 2023 |
| Dana-Farber Cancer Institute | Other | 5 | 2014 to 2018 |
| University of London | Academic | 5 | 2009 to 2022 |
| Duke University | Academic | 4 | 2010 to 2018 |
Showing 5 of 108 organizations.
Where ZBTB16 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
976 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.